FGF21 and type 2 diabetes mellitus: In the study by Kaufman et al., the administration of the long-acting fusion protein immunoglobulin 1 and FGF-21 (Ig1) Fc-FGF-21 (AKR-001) to T2DM patients with a BMI of 25–40 kg/m2 and An HbA1c of 6.5–10% or lower has not been shown to have a significant effect on weight reduction, as well as on FPG, FINS, fasting plasma glucagon, C-peptide, HOMA-IR, HDL-C, non-HDL-C, and TG [223].